All In Biotech

Free tool

FAERS Monitor: Iwilfin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215500 or its brand name (Iwilfin, Eflornithine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

42

Serious

31

74% of reports

Hospitalization

5

Death reported

13

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death7
  • deafness6
  • alopecia5
  • condition aggravated5
  • disease progression4
  • neuroblastoma4
  • disease recurrence2
  • dry mouth2
  • eyelash changes2
  • joint dislocation2
  • motor developmental delay2
  • off label use2
  • skin mass2
  • accident1
  • adverse drug reaction1

Reports by year received

View as table
YearReports
20061
20071
20131
20151
20161
20181
20201
20211
20221
20233
202418
20256
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eyelash changes25729.01469.56,369
neuroblastomaSignal45290.62071.716,027
motor developmental delay21740.6449.01,948
skin mass2150.038.8166
deafnessSignal6114.954.8569
joint dislocation294.824.5104
accident141.96.010
disease recurrence221.15.421
disease progressionSignal416.96.745
alopeciaSignal512.85.643
dry mouth212.33.211
condition aggravatedSignal58.23.625
adverse drug reaction15.60.81
deathSignal74.12.114
off label use21.10.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.